Drug approval delays in hematologic malignancies between Europe and the US and between Japan and the US: a clinical perspective.

Matsuda, Kensuke; Nagai, Sumimasa; Sugimoto, Koichi

Matsuda, Kensuke; Nagai, Sumimasa; Sugimoto, Koichi.

Matsuda K; Department of Hematology and Oncology, JR Tokyo General Hospital, Shibuya-ku, Japan.
Nagai S; Department of Medical Development, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Sugimoto K; Department of Hematology and Oncology, JR Tokyo General Hospital, Shibuya-ku, Japan.

Jpn J Clin Oncol ; 53(12): 1125-1129, 2023 Dec 07.

Article en En | MEDLINE | ID: mdl-37642224

Asunto(s)

Aprobación de Drogas; Neoplasias Hematológicas; Humanos; Japón/epidemiología; Factores de Tiempo; Neoplasias Hematológicas/tratamiento farmacológico; Europa (Continente)/epidemiología

Palabras clave

EMA; FDA; PMDA; drug approval delay; drug lag

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprobación de Drogas / Neoplasias Hematológicas Tipo de estudio: Prognostic_studies Límite: Humans País como asunto: Asia / Europa Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google